Permanence of Indocyanine Green in axillary lymph nodes three weeks after subdermal injection in patients with Breast Carcinoma and metastatic lymph nodes: The FLUO Trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513163-57-00

Enrollment

Registered

2024-10-11

Start date

2024-12-20

Completion date

Unknown

Last updated

2024-10-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

Frequency of patient with at least 3 fluorescent lymph nodes

Detailed description

Absolute frequency of total number of fluorescent lymph nodes per patient, Absolute frequency of lymph nodes in group A and in group B, Frequency of lymph nodes with metastases resulting fluorescent, Frequency of fluorescent and non-fluorescent lymph nodes between subgroups of patients with different demographic and clinical characteristics

Interventions

DRUGINDOCYANINE GREEN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Frequency of patient with at least 3 fluorescent lymph nodes	—

Secondary

Measure	Time frame
Absolute frequency of total number of fluorescent lymph nodes per patient, Absolute frequency of lymph nodes in group A and in group B, Frequency of lymph nodes with metastases resulting fluorescent, Frequency of fluorescent and non-fluorescent lymph nodes between subgroups of patients with different demographic and clinical characteristics	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026